Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03099174
What this trial is testing

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Who this might be right for
NeoplasmsBreast Neoplasms
Boehringer Ingelheim 133
Testing effectiveness (Phase 2)Looking for participantsNCT07222215
What this trial is testing

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Who this might be right for
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. Fanucci 297
Large-scale testing (Phase 3)Not Yet RecruitingNCT07784036
What this trial is testing

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Chengdu JOYO pharma Co., Ltd. 171
Testing effectiveness (Phase 2)Study completedNCT02069093
What this trial is testing

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 92
Early research (Phase 1)Ended earlyNCT04274933
What this trial is testing

Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Who this might be right for
Breast CancerCancer
AbbVie 4
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals 280
Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944434
What this trial is testing

FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 116
Testing effectiveness (Phase 2)UnknownNCT03910712
What this trial is testing

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Peking Union Medical College Hospital 250
Not applicableStudy completedNCT03921866
What this trial is testing

UK Ibrance Patient Program (IPP) Study

Who this might be right for
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Pfizer 191
Testing effectiveness (Phase 2)Ended earlyNCT02990845
What this trial is testing

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Premenopausal Breast Cancer
National Taiwan University Hospital 16
Testing effectiveness (Phase 2)Ended earlyNCT00752986
What this trial is testing

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

Who this might be right for
Breast Cancer
Genzyme, a Sanofi Company 39
Large-scale testing (Phase 3)Study completedNCT02482753
What this trial is testing

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Chipscreen Biosciences, Ltd. 365
Large-scale testing (Phase 3)Ended earlyNCT00097344
What this trial is testing

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasms, Hormone-Dependent
Intarcia Therapeutics 842
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Not applicableEnded earlyNCT01277926
What this trial is testing

Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 7
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Next Page